Author + information
- Received August 29, 2017
- Revision received November 27, 2017
- Accepted November 28, 2017
- Published online February 7, 2018.
- Tiffany M. Powell-Wiley, MD, MPHa,∗ (, )
- Julius Ngwa, PhDb,
- Selomie Kebede, MDb,
- Di Lu, MSc,
- Phillip J. Schulte, PhDd,
- Deepak L. Bhatt, MD, MPHe,
- Clyde Yancy, MDf,
- Gregg C. Fonarow, MDg and
- Michelle A. Albert, MD, MPHh
- aCardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
- bDivision of Cardiovascular Medicine, Howard University Hospital and School of Medicine, Washington, DC
- cDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
- dDepartment of Health Sciences Research, Mayo Clinic, Rochester, Minnesota
- eHeart and Vascular Center, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
- fCardiovascular Division, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
- gRonald Reagan University of California at Los Angeles Medical Center, Los Angeles, California
- hCenter for the Study of Adversity and Cardiovascular Disease (NURTURE Center), Cardiology Division, University of California at San Francisco Medical Center, San Francisco, California
- ↵∗Address for correspondence:
Dr. Tiffany M. Powell-Wiley, Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Room 5E-3340, Bethesda, Maryland 20892.
Objectives This study sought to evaluate the influence of race/ethnicity on the relationship between body mass index (BMI) and mortality in heart failure with preserved ejection fraction (HFpEF) and HF with reduced EF (HFrEF) patients.
Background Prior studies demonstrated an “obesity paradox” among overweight and obese patients, where they have a better HF prognosis than normal weight patients. Less is known about the relationship between BMI and mortality among diverse patients with HF, particularly given disparities in obesity and HF prevalence.
Methods The authors used Get With The Guidelines–Heart Failure data to assess the relationship between BMI and in-hospital mortality by using logistic regression modeling. The authors assessed 30-day and 1-year rates of all-cause mortality following discharge by using Cox regression modeling.
Results A total of 39,647 patients with HF were included (32,434 [81.8%] white subjects; 3,809 [9.6%] black subjects; 1,928 [4.9%] Hispanic subjects; 544 [1.4%] Asian subjects; and 932 [2.3%] other subjects); 59.7% of subjects had HFpEF, and 30.7% were obese. More black and Hispanic patients had Class I or higher obesity (BMI ≥30 kg/m2) than whites, Asians, or other racial/ethnic groups (p < 0.0001). Among subjects with HFpEF, higher BMI was associated with lower 30-day mortality, up to 30 kg/m2 with a small risk increase above 30 kg/m2 (BMI: 30 vs. 18.5 kg/m2), hazard ratio (HR) of 0.63 (95% confidence interval [CI]: 0.54 to 0.73). A modest relationship was observed in HFrEF subjects (BMI: 30 vs. 18.5 kg/m2; HR: 0.73; 95% CI: 0.60 to 0.89), with no risk increase above 30 kg/m2. There were no significant interactions between BMI and race or ethnicity related to 30-day mortality (p > 0.05).
Conclusions This work is one of the first suggesting the obesity paradox for 30-day mortality exists at all BMI levels in HFrEF but not in patients with HFpEF. Higher BMI was associated with lower 30-day mortality across racial/ethnic groups in a manner inconsistent with the J-shaped relationship noted for coronary artery disease. The differential slope of obesity and mortality among HFpEF and patients with HFrEF potentially suggests differing mechanistic factors, requiring further exploration.
The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute, the National Institutes of Health, or the U.S. Department of Health and Human Services. The Get With The Guidelines–Heart Failure program is provided by the American Heart Association, is sponsored, in part, by Amgen Cardiovascular, and has been funded in the past through support from Medtronic, GlaxoSmithKline, Ortho-McNeil, and the American Heart Association Pharmaceutical Roundtable. Dr. Powell-Wiley is supported by the Division of Intramural Research of the National, Heart, Lung, and Blood Institute of the National Institutes of Health. Dr. Bhatt is an advisory board member of Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; a member of the board of directors of Boston VA Research Institute, and Society of Cardiovascular Patient Care; a chair of the American Heart Association Quality Oversight Committee; is on the data monitoring committees of Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, and Population Health Research Institute; has received honoraria from the American College of Cardiology (senior associate editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (guest editor, associate editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (chief medical editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (secretary/treasurer), and WebMD (CME steering committees); has served on Clinical Cardiology (deputy editor), NCDR-ACTION Registry steering committee (chair), and VA CART Research and Publications Committee (chair); has received funding from Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, and The Medicines Company; receives royalties from Elsevier (editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease; is a site co-investigator for Biotronik, Boston Scientific, and St. Jude Medical; is a trustee for the American College of Cardiology; and has performed unfunded research for FlowCo, PLx Pharma, and Takeda. Dr. Fonarow has received research support from the Agency for Healthcare Research and Quality, and the National Institutes of Health; and is a consultant for Amgen, Janssen, Novartis, Medtronic, and St. Jude. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received August 29, 2017.
- Revision received November 27, 2017.
- Accepted November 28, 2017.
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.